Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 19, 2026.

New perspectives on central and peripheral immune responses to acute traumatic brain injury

Mahasweta Das, Subhra Mohapatra, Shyam S Mohapatra

Journal of Neuroinflammation · 2012 · Review · CC BY

doi:10.1186/1742-2094-9-236

Abstract

Traumatic injury to the brain (TBI) results in a complex set of responses involving various symptoms and long-term consequences. TBI of any form can cause cognitive, behavioral and immunologic changes in later life, which underscores the problem of underdiagnosis of mild TBI that can cause long-term neurological deficits. TBI disrupts the blood–brain barrier (BBB) leading to infiltration of immune cells into the brain and subsequent inflammation and neurodegeneration. TBI-induced peripheral immune responses can also result in multiorgan damage. Despite worldwide research efforts, the methods of diagnosis, monitoring and treatment for TBI are still relatively ineffective. In this review, we delve into the mechanism of how TBI-induced central and peripheral immune responses affect the disease outcome and discuss recent developments in the continuing effort to combat the consequences of TBI and new ways to enhance repair of the damaged brain.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Traumatic brain injury (TBI) is a complex process involving a broad spectrum of symptoms and long-term consequences including disabilities. It is a serious health problem in the United States and around the world. Recent data show that approximately 1.7 million people sustain a TBI annually including U.S. soldiers involved in combat operations and public safety personnel surviving terrorist attacks. An estimated 150 to 300,000 military personnel from Operation Iraqi Freedom and Operation Enduring Freedom suffered from TBI. It contributes to 30% of all injury-related deaths and costs about $60 billion annually. TBI of any form, mild to severe, can cause intellectual and cognitive deficits, mood and behavioral changes both short- and long-term. In the long term, these can cause potentially permanent changes and may lead to post-traumatic stress disorder (PTSD) in the general population as well as those in the military. Besides psychological symptoms, immune suppression from TBI and subsequent infections are important consequences.

Although TBI can range from mild to severe, most TBI is mild and characterized by brief changes in mental status and cognitive ability. Although the consequences of mild TBI are not readily appreciated, it can still cause infrastructural damage to the brain and secondary axonal injury and shows symptoms like cognitive or intellectual deficits and behavioral and personality changes even six months after injury. In most patients suffering from mild brain injury, the symptoms disappear within six months but many others suffer in a variety of ways that may be underappreciated and treated inadequately or improperly. Even under asymptomatic conditions, unhealed neurodegeneration may cause a spectrum of diseases with huge cost to society.

Once the brain suffers mechanical insult, the injury process evolves over time and includes (a) primary injury caused by direct or indirect contusion resulting in shearing or stretching of brain tissue, subdural hematoma and cerebral ischemia (b) secondary injury characterized by diffuse axonal injury and inflammatory reactions, and (c) regeneration. The secondary, that is, the nonmechanical injury phase, is progressive and lasts from hours to days, significantly contributing to neurological disabilities. Injury to the cerebral vasculature breaks the blood–brain barrier (BBB), allows entry of immune cells and stimulates inflammatory reactions. The molecular events result in apoptosis, inflammation, altered plasticity and neuronal regeneration. The complex nature of acute and chronic inflammatory reactions may aggravate the pathologic outcome or promote the repair process. Also, multiorgan damage in trauma patients can lead to elevated circulatory levels of inflammatory cytokines that may contribute to the post-TBI pathogenesis of the brain and cause multiple organ dysfunction syndrome (MODS) and death. In this review we discuss the mechanism of interaction between the systemic immune response and the brain after TBI and current novel treatment approaches to combat TBI-induced damage (Figure 1).

Response of the central nervous system to TBI: neuroinflammation and pathobiology of the CNS

The BBB protects the brain and maintains the homeostasis. Following TBI, a massive release of excitatory amino acid neurotransmitters, particularly glutamate, takes place. These molecules interact with neurons and astrocytes and cause increased Ca2+, Na+, and K+ fluxes through overstimulation of glutamate receptors. As a consequence, catabolic processes are activated resulting in BBB breakdown. The kinin system, excitotoxicity, activation of the innate immune system leading to neutrophil recruitment, mitochondrial alterations and microglial activation lead to generation of reactive oxygen species (ROS) which in turn trigger downstream pathways and cause oxidative damage, modifications in tight junctions and matrix metalloproteinase (MMP) activation. Thus ROS play an important role in mediating TBI-induced changes in BBB permeability. ROS have also been implicated in fungal toxin T-2-mediated alteration in BBB permeability. Recent animal studies have shown that BBB breakdown involves transcriptional changes in the neurovascular network and eventual neurodegeneration.

The leaky BBB allows the passage of inflammatory molecules and cells into and out of the injured brain initiating a cascade of responses in the brain and other organs. The most important events contributing toward the pathology of TBI are reactive astrogliosis, microglial activation, infiltration of immune cells in the CNS and neurodegeneration. Both the primary and secondary mechanisms of TBI cause neurodegeneration and contribute to post-traumatic neurological deficits. One of the major pathological outcomes of these mechanisms is diffuse axonal injury (DAI), the main clinical feature of human TBI, leading to diffuse degeneration of cerebral white matter. In a rodent model of diffuse TBI, Cernak et al. have shown hypertension, brain edema, increased permeability of BBB, DAI and apoptosis of the cerebral cells following a high velocity impact. Alder et al. have characterized the pathological and behavioral changes in a lateral fluid percussion model (LFPI) of TBI in mice. The process of TBI-induced neuronal cell death has multiple, overlapping and distinct molecular mechanisms. Following TBI, neuronal cell death can be induced by caspase-dependent or -independent pathways, by cell cycle activation in which mature neuronal cells reenter the cell cycle and then die or by autophagy. In the caspase-dependent pathways, caspase 3 appears to play the major role in causing TBI-induced apoptosis, although caspase 6 and 7 have also been acknowledged as proapoptotic molecules. The caspase-independent pathway is more complex and involves mitochondrial proapoptotic molecules including apoptosis-inducing factor (AIF) and its regulators like PARP-1, cyclophilin and heat shock protein-70 (HSP-70). These mechanisms probably work together in stress-induced neuronal cell death and, therefore, inhibition of only one pathway may not be sufficient to protect neurons after TBI (Table 1).

Role of neurocytokines and neurochemokines in the central response to TBI

In the 1980s, scientists observed that the brain, endocrine system and immune system function together to maintain homeostasis in health and prevent disease. After Spangelo and co-workers identified cytokines and their role in inflammation and immunity, brain researchers began to study the actions of cytokines in the CNS. In 1992, Ban et al. found that interleukin-1β (IL-1β) was synthesized in the brain under pathological conditions while others showed that peripherally synthesized cytokines were transported to the brain via the bloodstream or cerebrospinal fluid (CSF) and secreted into the brain parenchyma during breakdown of the BBB, thus linking the brain and immune system. The chemokines are the chemotactic cytokines that play an important role in leukocytes migration. Their role in signaling in the CNS was reported by investigators in the late 1990s. Under inflammatory or neurodegenerative conditions in the CNS, chemokine molecules are synthesized by activated microglia or astrocytes which take part in the defense of the CNS by recruiting monocytes to the injury site. Under normal physiological conditions the tight junctions of the BBB prevent infiltration of circulating leukocytes into the brain parenchyma. Pathological conditions like infections, mechanical trauma or toxicity may disrupt the BBB and allow immune cells to enter the brain parenchyma in response to chemokine signaling from resident immune cells.

In addition to macrophages and glial cells, neurons have also been found to express chemokines and chemokine receptors in the brain under physiological and pathological conditions. Fractalkine (CX3CL1) was the first chemokine seen to be constitutively expressed by the neuronal cells of the CNS. Later, other chemokines like CXCL14/BRAK;, CCL20, CCL21, CXCL12/SDF-1 and CCL2/MCP-1, were found in neuronal cells under various pathological conditions including TBI. Helmy et al. have reviewed the temporal profile of 42 cytokines after TBI in human patients. Upregulation of CCL20 has been observed in human subjects one day after severe TBI. Furthermore, a recent study identified CCL20 as a dual-acting chemokine with the potential for inhibiting immune reactions and more importantly in attracting inflammatory effectors and activators. Studies in our laboratory showed cerebral as well as systemic expression of CCL20 after mild TBI in rats. Recently, Biber and co-workers showed that damaged neurons produce CCL21, which assumes a neuromodulatory function. In a spinal cord injury model, Zhao et al. have shown that CCL21 expressed by the damaged neurons used the CXCR3 receptor instead of the usual CCR7 receptor to activate the local microglial cells and initiate inflammatory reactions. These neurochemokines can also be involved in nonimmune-related functions like neuromodulation or neurotransmission, which could be important in TBI. As Rostene and colleagues have pointed out, this could be the complex communication network between the neurons and the cells in its microenvironment that informs them about the damage.

In addition to chemokines, various cytokines have also been reported to be expressed following TBI, including TNF-α associated with activated microglia and astrocytes that may initiate the inflammatory process. IL-6 in the injured brain has been associated with reactive astrogliosis, neuronal injury, and infiltration of peripheral cells. TGF-β expression in the astrocytes and microglia after injury has been implicated in the pathology and dysfunction of the CNS and IL-1, IL-6, IL-8, IL-10, granulocyte colony-stimulating factor, TNF-α, FAS ligand and monocyte chemo-attractant protein 1 are thought to account for the progressive injury. In a rat fluid percussion injury model a biphasic production of TGF-β, mainly of TGF-β 2, was detected in the ipsilateral cortex, with a first peak at 30 minutes and a second peak at 48 hours after the lesion. This response was accompanied by transient production of TNF-α and IL-6 occurring between five and eighteen hours after trauma. From this temporal pattern, Rimaniol et al. suggested an alternative pro- and anti-inflammatory role of TGF-β in the regulation of the brain cytokine network providing an endogenous mechanism for the control of the inflammatory reaction in traumatic brain injury.

Activation of resident immune cells of the CNS following TBI

Microglial activation is integral to the response of the brain and spinal cord to injury. A number of factors including pro-inflammatory and anti-inflammatory cytokines, chemokines, growth factors, nitric oxide, prostaglandins, and superoxide and other reactive oxygen species are released by microglia and modulate secondary injury as well as recovery after injury. Microglial activation is regulated in part by poly(ADP-ribose) polymerase-1 (PARP-1). Using a PARP-knockout mouse model of TBI, Whalen et al. showed improved motor and cognitive functions after TBI and thereby indicated a detrimental role of PARP in the pathogenesis of TBI. In 2006, Bernardo and colleagues observed that inhibition of microglial activation by peroxisome proliferator-activated receptor (PPAR)-gamma and its synthetic agonists by expression of surface antigens, synthesis of nitric oxide, prostaglandins, inflammatory cytokines and chemokines by TBI-induced brain inflammation could be controlled. Perivascular macrophages are reactive cells that produce IL-1β and TNFα after CNS injury. In the perivascular endothelium these cytokines induce the expression of adhesion molecules and promote leukocyte infiltration.

Response of the peripheral immune system to TBI: systemic immune activation and suppression after TBI

Multi-organ damage following TBI can lead to increased numbers of infiltrating inflammatory cells and levels of cytokines in the brain. Because of the compromised BBB, these cells and molecules gain access to the brain and aggravate the pathogenesis of TBI. In spite of the importance of systemic inflammation and circulating inflammatory molecules in TBI, only limited investigations have been performed in this area. In a study on rats, Whalen et al. observed systemic neutrophilia together with increased BBB permeability when granulocyte-colony stimulating factor (GCSF) was administered prior to cortical contusion injury (CCI). In another study Utagawa et al. demonstrated that systemically administered IL-1β markedly influenced the histopathological and behavioral outcome following fluid percussion injury. The leaking of pro-inflammatory molecules like cytokines, arachidonic acid metabolites, proteins of the contact-phase and coagulation systems, complement factors and acute-phase proteins, as well as hormonal mediators through the compromised BBB into the circulation may generate a systemic immune response syndrome (SIRS) characterized by hyper-inflammation or may release anti-inflammatory molecules targeting IL-1β, IL-6 or TNFα resulting in compensatory anti-inflammatory response syndrome (CARS) to block development of SIRS.

The production of inflammatory mediators is regulated by the negative feedback provided by the hypothalamus-pituitary-adrenal (HPA) axis and sympathetic nervous system (SNS) efferent limbs in CARS; but in TBI, an imbalance between these two can lead to immunological dysfunction like organ damage or susceptibility to infections. Stress-mediated release of cortisol and catecholamines can enhance the immune suppression. Direct infection through a skull fracture in TBI or from the transmigration of enteric bacteria after a closed head injury may cause infection, pneumonia and sepsis which can be life threatening in TBI or immune-compromised patients. Griffin has also pointed out that immune suppression after TBI causes retardation of healing in the brain infrastructure. In a 2001 human study, severe immune suppression was observed following severe TBI. Eighteen to seventy-two hours after head trauma, the numbers of circulating T-cells, T-helper cells, T-suppressor and NK cells were reduced while the B-lymphocyte count remained normal. There was also an increase in CD4+/CD45+ T cells. The immune regulatory functions within the CNS following TBI, for example, microglia and astrocyte activation lead to antigen presentation to T-cells that alters their cytokine response and this may contribute to TBI pathology. On the other hand, the ability of these neuroantigen-reactive T cells to specifically infiltrate the CNS can be used to deliver molecules to augment a recovery response in degenerating CNS tissues.

Response of peripheral immune organs to TBI

Despite ongoing research, the effect of TBI on other organs is largely unknown. In one study Mirzayan et al. evaluated the histopathological changes in lung and liver. Following a single TBI event, they observed migration of immunocompetent cells to peripheral organs leading to various degrees of organ dysfunction. The spleen is a reservoir of peripheral macrophages and other immune cells in the body, and it is now well known that splenic signaling contributes to injury of various tissues after ischemic insult. For example, splenectomy prior to insult protects both the liver and brain from ischemic damage. They have also observed a reduction in spleen size following ischemic insult 84]. Li et al. showed that splenectomy immediately after severe TBI induced by weight drop in rats decreased pro-inflammatory cytokine production, mortality rate and improved cognitive function. It was observed by Das et al. that splenectomy immediately after the induction of mild TBI by lateral fluid percussion in rats attenuated neurodegeneration and CCL20 chemokine expression in the brain. Although the mechanism of spleen-brain interaction is not clear, it was found by Lee et al. that the spleen participates in cerebral inflammation following intracerebral hemorrhage in a stroke model, as splenectomy reduced cerebral edema and inflammatory cell counts (probably by increased circulating catecholamines). Stewart and McKenzie suggested that sympathetic stimulation can cause the release of immune cells from the spleen and subsequent infiltration into brain tissues. Regardless of the neural mechanism, removal of the spleen immediately after the insult would remove the largest pool of immune cells, which should decrease infiltration and consequent neuroinflammation. The thymus is the major source of maturing T-cells in the body. Although a great deal of investigation has been done to elucidate the relationship between brain trauma and the immune system, very little has been done to explore the function of the thymus after TBI. In a study of LFPI in rats, Das et al. found elevated CCL20 expression in the thymus following TBI. Further investigation is needed to identify the specific function of thymus after TBI in adult rats. In a model of polytrauma combined with shock, Guan et al. observed apoptosis in the thymus, spleen, lung, liver and intestine which could cause the early organ injury and late organ failure seen in polytrauma patients. In an effort to elucidate the hepatic response to acute brain injury, Campbell et al. observed that clodronate-mediated Kupffer cell (KC) depletion reduced neutrophil- and ED-1-positive macrophage infiltration in IL-1β-injected brain or contusion-injured spinal cord by 70% and 50% respectively. Suppression of KC proliferation may, therefore, reduce secondary injury. Previously this group had pointed out that hepatic cytokines or chemokines produced as a result of acute injury may inhibit neutrophil recruitment to the CNS. In recent studies, decreased liver weight and protein content, altered energy metabolism and p450 dysfunction have been observed following TBI.

Cytokines and chemokines secreted peripherally control TBI

Following TBI, the signaling pathways are activated, inflammatory cells are mobilized and there is enhanced secretion of multiple inflammatory mediators like cytokines, chemokines and damage-associated molecular patterns (DAMPs). DAMPs in turn reactivate the inflammatory mediators and aggravate the damage. The exact role of cytokines in brain trauma is not fully known, although experimental evidences suggest that cytokines play a major role in the body’s response to TBI. The major cytokines produced after TBI include tumor necrosis factor–alpha (TNF-α), IL-1β, IL-2, IL-6, IL-8,, IL-4 and IL-18. Free radical nitric oxide (NO) is produced by the enzyme inducible NO synthase (iNOS), which is an important inflammatory mediator after trauma in mice. Among peripherally secreted chemokines in response to TBI the role of CCL20 has recently been described. This unique chemokine interacts specifically with the CC chemokine receptor 6 (CCR6) and induces chemotaxis of dendritic cells, T cells and B cells. These cells are residents of the spleen and have the potential to promote neuroinflammation. CCL20 is expressed in inflamed epithelial cells and in the synovial tissues of rheumatoid arthritis patients. It has also been shown to be upregulated under normothermic conditions in a rat middle cerebral artery occlusion (MCAO) model. Upregulation of CCL20 along with other cytokines has been observed in human subjects one day after severe traumatic brain injury. Furthermore, CCL20 has been identified as a dual-acting chemokine with the potential for inhibiting immune reactions and more importantly in attracting inflammatory effectors and activators. In a recent study using the LFPI rat model of TBI, Das et al. showed the expression of CCL20 mRNA and protein in spleen and thymus 24 hours after TBI, which is 24 hours before its expression in the brain. Since the thymus is the major source of mature circulating T cells, CCL20 expression in the thymus in adult rats as observed in this study seems significant and should be further investigated.

Is TBI associated with other neurodegenerative disorders?

There is increasing evidence showing that TBI is associated with neurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), and amyotropic lateral sclerosis (ALS). Epidemiological data indicates a single TBI event may trigger or accelerate the onset of Alzheimer’s disease (AD) in later life. On the other hand, repetitive mild TBI has been associated with progressive neurodegeneration. Since, Rudelli et al. reported a case of classic AD pathology in a 38 year old severe head trauma patient, both tau pathologies and Aβ plaques were identified in survivors of single TBI Subsequently, cases of AD-like pathology including neurofibrillary tangles and Aβ deposition were reported in head trauma victims, including boxers, irrespective of age. Although the Aβ plaques in AD and TBI are morphologically different, both contain primarily Aβ1- 42 with some occurrence of Aβ1-40 in TBI. Aβ1-42 has also been observed in the CSF of severe TBI patients and is thought to be directly related to the increased level of cerebral Aβ and neuronal amyloidogenic amyloid precursor protein (APP) levels after TBI. Although results of animal studies on TBI induced AD pathologies are conflicting, it has been observed that post TBI activation of microglia and proinflammatory cytokine release exacerbates the AD like pathologies in rats and is involved in APP processing that leads to generation of Aβ plaques.

In contrast to AD, studies attempting to correlate TBI and MS, another neurodegenerative, demyelinating disease of the CNS, are limited. Goldacre and colleagues and Kurland found no evidence of association between TBI and the development of MS. However, risk analysis using Taiwan’s National Health Insurance Research Database, indicated higher risk of incidence of MS in patients with a history of TBI compared to non TBI control group. Parkinson’s disease (PD) is a neurodegenerative disorder, which affects the dopaminergic neurons of the substantia nigra. PD-associated mitochondrial dysfunction and pathology was observed after mild to moderate TBI and trichloroethylene (TCE) exposure in rats. Also, TBI was reported to cause the nigrostriatal dopaminergic neurodegeneration in a rat model of LFPI suggesting that TBI is a risk factor of PD development. Thus, although TBI appears to be associated with the development of some neurodegenerative diseases, conflicting data exist and detailed human and animal studies are necessary in this field. The most studied association between TBI and AD appears to suggest that TBI activation of immune mechanisms and proinflammatory cytokine activation of microglia contribute to neurodegenerative processes.

Therapeutic approaches for TBI

A number of drugs for TBI have been tested in clinical trials but none has shown much promise. Most of the approaches to TBI therapy aim at treating the secondary neurodegeneration as a single component. Recently, a therapeutic regimen using multifunctional drugs has been proposed and tested in experimental neurotrauma models. The therapeutic agents included hormones like thyrotropin releasing hormone (TRH) and progesterone, heat shock proteins, neurotrophic factors, erythropoietin, statin drugs and antibiotics, substance P antagonists, cyclosporine, and magnesium salts among others.

Anti-inflammatories for TBI

The inflammation following TBI causes tissue damage correlating with the secondary injury phase. Recently much attention has been drawn to the potential therapeutic benefits of inhibiting reactive oxygen species (ROS), reactive nitrogen species (RNS), and several types of tissue-digesting enzymes (matrix metalloproteinases), prostanoids, leukotrienes, and proinflammatory/inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α). Inhibition of TNF-α with cannabinoids like pentoxifylline and dexanabinol, and use of corticosteroids or NSAIDs like ibuprofen or minocycline to reduce inflammation in the brain have shown promise in animals but failed in clinical trials. Corticosteroids are a family of anti-inflammatory drugs that are widely used in autoimmune and allergic conditions and to reduce tumor-induced cerebral edema; but they failed to show any benefit in human trials of TBI involving adults and children. Reduction of oligodendrocyte death and axonal degeneration by minocycline, a tetracycline derivative was observed in a spinal cord injury model. Cederberg et al. suggested that timing is crucial in inflammatory intervention, as IL-1, IL-6, and TNF-α may also play an anti-inflammatory role in a later stage of TBI-induced brain inflammation. Also, the PPAR-gamma agonist 15d-prostaglandin J(2) was shown to control brain inflammation by inhibiting microglial activation after TBI.

Gene therapy for TBI

Gene therapy is a promising approach for the treatment of several diseases and conditions including TBI. With the advent of improved experimental techniques like microarrays for gene expression analysis, new targets are emerging for the treatment of diseases, drug development, immunotherapeutics and gene therapy. Colak et al. have identified several gene networks potentially involved in TBI that includes the C1ql2, Cbnl, Sdc1, Bdnf, MMP9, and Cd47 genes. Redell et al. observed changes in hippocampal miRNA expression corresponding to the pathophysiological changes following injury and identified these as potential targets for gene therapy. Degeorge and coworkers demonstrated that administration of viral-mediated glial cell-line derived neurotrophic factor (AdGDNF) one week prior to cortical contusion injury in rats resulted in neuroprotection but not functional recovery. Attempts have been made to target mRNA translational regulation to combat neurodegeneration. Aberrant RNA oxidation, RNA degradation, altered RNA splicing and ribosomal changes – all leading to mRNA translational abnormalities have been described by many authors in different neurodegenerative conditions. The mRNA translational regulation is affected by small non-coding microRNAs. The miRNA-argonaute complex suppresses the translation of target mRNA and each miRNA can regulate the translation of hundreds of mRNA targets and control the expression of many genes. Under cellular stress, a subset of microRNAs increases while expression of other miRNAs is decreased. High throughput sequencing has shown that the human brain expresses over 1000 miRNAs, the functions of only approximately 500 of which have been determined. MiRNAs have been implicated in various neurodegenerative conditions including TBI. Using microarray analysis, Redell and coworkers observed changes in the hippocampal expression levels of 444 miRNAs at 3 and 24 hours after controlled cortical impact injury in rats. In this study, 50 miRNAs were overexpressed including targets for proteins known to be initiated after injury. Lei et al. also observed up- and down-regulation of rat cerebral miRNA up to 72 hours after TBI while Liu et al. reported altered miRNA profiles after traumatic spinal cord injury in mice. The potential exists for using miRNAs and small interfering RNAs (siRNAs) as therapeutic agents, but much work needs to be done before they will become a regular part of the physician’s tool kit. The si/miRNAs can be delivered using various transfection agents including liposomes, polyethylenimine (PEI), chitosan nanoparticles or by electroporation. Apart from the potential disadvantage of off-target effects, RNA knockdown can be useful in treating TBI.

Transplantation-based approaches for treating TBI

In the past two decades, restorative therapeutic approaches focusing on repair or replacement of damaged or dead cells following TBI have gained importance. Cellular transplantation is the method of choice because the brain itself has a limited capacity for self-repair. Early experiments with transplantation of fetal neural tissues with or without nerve growth factor (NGF) were effective, but raised issues of practicality and ethics. NT2N cells showed promise in graft survival. It was found that ex vivo NGF gene therapy improved cognitive deficits following CCI in rodents. Both rodent and human embryonic stem cells have shown encouraging results in survival, integration and attenuation of post-traumatic sequellae. Stem cells have the ability to self- renew and differentiate depending on specific cues. Neural stem cells in particular can divide unlimitedly and differentiate into neurons or glial cells. It was observed that E14.5 mouse embryonic stem cells transplanted with or without a fibronectin scaffold following CCI improved behavioral symptoms. Xenotransplanted human neural stem cells have been found to survive in injured rodent brains and to express astrocytic and neuronal antigens. They migrated to the hippocampus, corpus callosum and ipsilateral sub-ependymal zone and decreased the number of degenerating neurons. Bone marrow-derived stem cells (BMSCs), either hematopoietic or mesenchymal, are advantageous in that they can be harvested from the same animal and thereby avoid the problems of cell availability and immune rejection. These cells have successfully been transplanted into injured rats by different routes where they express neural and glial cell markers (35, 36) and migrate to the subventricular zone, hippocampus and pericontusional areas indicating neurogenesis and improved neurobehavioral outcome. Ma et al. transplanted neural stem cells (NSCs) modified to encode brain derived neurotrophic factor (BDNF) in rats after TBI and found significant improvement in graft survival, neurogenesis and behavioral outcome. In another study in Wistar rats, functional improvement and colonization of BMSCs were observed after TBI and the recovery was found to be facilitated by granulocyte colony stimulating factor (G-CSF). Human fetal neural stem cells (hfNPCs) transplanted after CCI in SD rats increased angiogenesis and reduced astrogliosis. As a long term effect they observed functional improvement, reduced lesion volume and increased neuronal survival surrounding the lesion.

The potential of therapeutic transplantation of immortalized progenitor cell lines after TBI, has also been tested by various authors. HiB5 cells derived from embryonic rat hippocampus, MHP36, the fibroblast growth factor 2 (FGF-2)-responsive Maudsley hippocampal cell line clone 36 and C17.2, which is a clonal multipotent progenitor cell from murine cerebellum, have been tested for their efficacy in improving repair of the contusion site, migration, neurogenesis and neurobehavioral outcome. Hunang et al. reviewed successful preclinical studies and clinical trials of cell-based therapeutics for different neurodegenerative conditions including TBI. They mentioned the use of restorative transplantation involving fetal/embryonic brain and spinal cord tissue, stem cells including embryonic, neural, hematopoietic, adipose-derived adult stem/precursor cells, skin-derived precursor and induced pluripotent stem cells, glial cells (Schwann cells, oligodendrocyte, olfactory ensheathing cells, astrocytes, microglia, tanycytes), neuronal cells (various phenotypic neurons and Purkinje cells), mesenchymal stromal cells originating from bone marrow, umbilical cord, and umbilical cord blood, epithelial cells derived from the layer of retina and amnion, menstrual blood-derived stem cells, Sertoli cells, and active macrophages. Functional recovery and angiogenesis were observed following transplantation of endothelial progenitor cells derived from adipose tissues in the injured rat brain showing promise. Some of these approaches have also gone to clinical trials for SCI/TBI, and the clinical and scientific communities are paying more attention to the restorative treatment options for TBI.

Conclusion

Traumatic brain injury is a complex process evoking systemic immune responses as well as direct local responses in the brain tissues. The primary or direct damage disrupts the BBB and injures the neurons. This initiates a cascade of inflammatory reactions including chemokine production and activation of resident immune cells. The leakage of the inflammatory molecules through the compromised BBB attracts peripheral immune cells to the site of injury. The effect of TBI is not restricted to the brain; it can cause multi-organ damage and evoke systemic immune response including cytokine and chemokine production. This facilitates the recruitment of immune cells to the site of injury and progression of the inflammatory reaction and subsequent repair processes. In spite of the socioeconomic burden of TBI and worldwide research efforts, an effective treatment is still not available. Translational regulation of mRNA by si/mi RNA shows promise as a safe and specific treatment to combat neurodegeneration. Transplantation-based therapies also have the potential to repair and restore brain structure and function but continued in-depth investigations are needed before they become successful therapeutics.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

MD has researched and prepared the manuscript; SM and SSM have made critical suggestions on the content and reviewed the manuscript. All authors have read and approved the final manuscript.

References 181

  1. 1.

    Faul M Xu L Wald MM Coronado VG Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths2010 Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta (GA)

    Not in our library

  2. 2.

    Rostene W Dansereau MA Godefroy D Van Steenwinckel J Reaux-Le Goazigo A Melik-Parsadaniantz S Apartis E Hunot S Beaudet N Sarret P Neurochemokines: a menage a trois providing new insights on the functions of chemokines in the central nervous systemJ Neurochem2011 118680694

    Not in our library10.1111/j.1471-4159.2011.07371.x

  3. 3.

    Fabrizio KS Keltner NL Traumatic brain injury in operation enduring freedom/operation iraqi freedom: a primerNurs Clin North Am2010 45569580vi

    Not in our library10.1016/j.cnur.2010.06.003

  4. 4.

    Galarneau MR Woodruff SI Dye JL Mohrle CR Wade AL Traumatic brain injury during operation Iraqi freedom: findings from the United States navy-marine corps combat trauma registryJ Neurosurg2008 108950957

    Not in our library10.3171/jns/2008/108/5/0950

  5. 5.

    Macgregor AJ Dougherty AL Galarneau MR Injury-specific correlates of combat-related traumatic brain injury in Operation Iraqi FreedomJ Head Trauma Rehabil2011 26312318

    Not in our library10.1097/htr.0b013e3181e94404

  6. 6.

    Ettenhofer ML Abeles N The significance of mild traumatic brain injury to cognition and self-reported symptoms in long-term recovery from injuryJ Clin Exp Neuropsychol2009 31363372

    Not in our library10.1080/13803390802175270

  7. 7.

    Ettenhofer ML Barry DM A comparison of long-term postconcussive symptoms between university students with and without a history of mild traumatic brain injury or orthopedic injuryJ Int Neuropsychol Soc2012 18451460

    Not in our library10.1017/s1355617711001895

  8. 8.

    Halldorsson JG Flekkoy KM Arnkelsson GB Tomasson K Magnadottir HB Arnarson EO The scope of early traumatic brain injury as a long-term health concern in two nationwide samples: prevalence and prognostic factorsBrain Inj2012 26113

    Not in our library10.3109/02699052.2011.635359

  9. 9.

    Ozen LJ Fernandes MA Slowing down after a mild traumatic brain injury: a strategy to improve cognitive task performance?Arch Clin Neuropsychol2012 2785100

    Not in our library10.1093/arclin/acr087

  10. 10.

    Griffin GD The injured brain: TBI, mTBI, the immune system, and infection: connecting the dotsMil Med2011 176364368

    Not in our library10.7205/milmed-d-10-00021

  11. 11.

    Centers for Disease Control and PreventionConcussion and Mild TBIhttp://www.cdc.gov/concussion

    Not in our library

  12. 12.

    Kraus MF Susmaras T Caughlin BP Walker CJ Sweeney JA Little DM White matter integrity and cognition in chronic traumatic brain injury: a diffusion tensor imaging studyBrain2007 13025082519

    Not in our library10.1093/brain/awm216

  13. 13.

    McIntosh TK Smith DH Meaney DF Kotapka MJ Gennarelli TA Graham DI Neuropathological sequelae of traumatic brain injury: relationship to neurochemical and biomechanical mechanismsLab Invest1996 74315342

    Not in our library

  14. 14.

    Cernak I Animal models of head traumaNeuroRx2005 2410422

    Not in our library10.1602/neurorx.2.3.410

  15. 15.

    DeKosky ST Kochanek PM Clark RS Ciallella JR Dixon CE Secondary injury after head trauma: subacute and long-term mechanismsSemin Clin Neuropsychiatry1998 3176185

    Not in our library

  16. 16.

    Lucas SM Rothwell NJ Gibson RM The role of inflammation in CNS injury and diseaseBr J Pharmacol2006 147Suppl 1S232S240

    Not in our library10.1038/sj.bjp.0706400

  17. 17.

    Werner C Engelhard K Pathophysiology of traumatic brain injuryBr J Anaesth2007 9949

    Not in our library10.1093/bja/aem131

  18. 18.

    Utagawa A Truettner JS Dietrich WD Bramlett HM Systemic inflammation exacerbates behavioral and histopathological consequences of isolated traumatic brain injury in ratsExp Neurol2008 211283291

    Not in our library10.1016/j.expneurol.2008.02.001

  19. 19.

    Lu J Goh SJ Tng PY Deng YY Ling EA Moochhala S Systemic inflammatory response following acute traumatic brain injuryFront Biosci2009 1437953813

    Not in our library10.2741/3489

  20. 20.

    Bramlett HM Dietrich WD Pathophysiology of cerebral ischemia and brain trauma: similarities and differencesJ Cereb Blood Flow Metab2004 24133150

    Not in our library10.1097/01.wcb.0000111614.19196.04

  21. 21.

    Robertson CL Bell MJ Kochanek PM Adelson PD Ruppel RA Carcillo JA Wisniewski SR Mi Z Janesko KL Clark RS Marion DW Graham SH Jackson EK Increased adenosine in cerebrospinal fluid after severe traumatic brain injury in infants and children: association with severity of injury and excitotoxicityCrit Care Med2001 2922872293

    Not in our library10.1097/00003246-200112000-00009

  22. 22.

    Pun PB Lu J Moochhala S Involvement of ROS in BBB dysfunctionFree Radic Res2009 43348364

    Not in our library10.1080/10715760902751902

  23. 23.

    Ravindran J Agrawal M Gupta N Lakshmana Rao PV Alteration of blood brain barrier permeability by T-2 toxin: role of MMP-9 and inflammatory cytokinesToxicology2011 2804452

    Not in our library10.1016/j.tox.2010.11.006

  24. 24.

    Shlosberg D Benifla M Kaufer D Friedman A Blood–brain barrier breakdown as a therapeutic target in traumatic brain injuryNat Rev Neurol2010 6393403

    Not in our library10.1038/nrneurol.2010.74

  25. 25.

    Faden AI Neuroprotection and traumatic brain injury: theoretical option or realistic propositionCurr Opin Neurol2002 15707712

    Not in our library10.1097/00019052-200212000-00008

  26. 26.

    Cernak I Vink R Zapple DN Cruz MI Ahmed F Chang T Fricke ST Faden AI The pathobiology of moderate diffuse traumatic brain injury as identified using a new experimental model of injury in ratsNeurobiol Dis2004 172943

    Not in our library10.1016/j.nbd.2004.05.011

  27. 27.

    Adams JH Doyle D Ford I Gennarelli TA Graham DI McLellan DR Diffuse axonal injury in head injury: definition, diagnosis and gradingHistopathology1989 154959

    Not in our library10.1111/j.1365-2559.1989.tb03040.x

  28. 28.

    Gennarelli TA Thibault LE Tipperman R Tomei G Sergot R Brown M Maxwell WL Graham DI Adams JH Irvine A Axonal injury in the optic nerve: a model simulating diffuse axonal injury in the brainJ Neurosurg1989 71244253

    Not in our library10.3171/jns.1989.71.2.0244

  29. 29.

    Alder J Fujioka W Lifshitz J Crockett DP Thakker-Varia S Lateral fluid percussion: model of traumatic brain injury in miceJ Vis Exp2011 54

    Not in our library10.3791/3063

  30. 30.

    Zhang X Chen J Graham SH Du L Kochanek PM Draviam R Guo F Nathaniel PD Szabo C Watkins SC Clark R Intranuclear localization of apoptosis-inducing factor (AIF) and large scale DNA fragmentation after traumatic brain injury in rats and in neuronal cultures exposed to peroxynitriteJ Neurochem2002 8218191

    Not in our library10.1046/j.1471-4159.2002.00975.x

  31. 31.

    Ravagnan L Roumier T Kroemer G Mitochondria, the killer organelles and their weaponsJ Cell Physiol2002 1921317

    Not in our library10.1002/jcp.10111

  32. 32.

    Stoica BA Byrnes KR Faden AI Cell cycle activation and CNS injuryNeurotox Res2009 1622137

    Not in our library10.1007/s12640-009-9050-0

  33. 33.

    Bredesen DE Programmed cell death mechanisms in neurological diseaseCurr Mol Med2008 817386

    Not in our library10.2174/156652408784221315

  34. 34.

    Yakovlev AG Faden AI Caspase-dependent apoptotic pathways in CNS injuryMol Neurobiol2001 2413144

    Not in our library10.1385/mn:24:1-3:131

  35. 35.

    Cregan SP Fortin A MacLaurin JG Callaghan SM Cecconi F Yu SW Dawson TM Dawson VL Park DS Kroemer G Slack RS Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell deathJ Cell Biol2002 15850717

    Not in our library10.1083/jcb.200202130

  36. 36.

    Hong SJ Dawson TM Dawson VL Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signalingTrends Pharmacol Sci2004 2525964

    Not in our library10.1016/j.tips.2004.03.005

  37. 37.

    Whalen MJ Clark RS Dixon CE Robichaud P Marion DW Vagni V Graham SH Virág L Haskó G Stachlewitz R Szabó C Kochanek PM Reduction of cognitive and motor deficits after traumatic brain injury in mice deficient in poly(ADP-ribose) polymeraseJ Cereb Blood Flow Metab1999 1983542

    Not in our library10.1097/00004647-199908000-00002

  38. 38.

    Galat A Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity–targets–functionsCurr Top Med Chem2003 3131547

    Not in our library10.2174/1568026033451862

  39. 39.

    Cande C Vahsen N Kouranti I Schmitt E Daugas E Spahr C Luban J Kroemer RT Giordanetto F Garrido C Penninger JM Kroemer G AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysisOncogene2004 23151421

    Not in our library10.1038/sj.onc.1207279

  40. 40.

    Yasuda H Shichinohe H Kuroda S Ishikawa T Iwasaki Y Neuroprotective effect of a heat shock protein inducer, geranylgeranylacetone in permanent focal cerebral ischemiaBrain Res2005 103217682

    Not in our library10.1016/j.brainres.2004.11.009

  41. 41.

    Stoica BA Faden AI Cell death mechanisms and modulation in traumatic brain injuryNeurotherapeutics2010 7312

    Not in our library10.1016/j.nurt.2009.10.023

  42. 42.

    Stirling DP Khodarahmi K Liu J McPhail LT McBride CB Steeves JD Ramer MS Tetzlaff W Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injuryJ Neurosci2004 24218290

    Not in our library10.1523/jneurosci.5275-03.2004

  43. 43.

    Helmy A Carpenter KL Menon DK Pickard JD Hutchinson PJ The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal productionJ Cereb Blood Flow Metab2010 6812635

    Not in our library10.1038/jcbfm.2010.142

  44. 44.

    Comerford I Bunting M Fenix K Haylock-Jacobs S Litchfield W Harata-Lee Y Turvey M Brazzatti J Gregor C Nguyen P Kara E McColl SR An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation? CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune diseaseBioessays2010 32106776

    Not in our library10.1002/bies.201000063

  45. 45.

    Das M Leonardo CC Rangooni S Pennypacker K Mohapatra S Mohapatra SS Lateral fluid percussion injury of the brain induces CCL20 inflammatory chemokine expression in ratsJ Neuroinflammation2011 8148

    Not in our library10.1186/1742-2094-8-148

  46. 46.

    Biber K Rappert A Kettenmann H Brouwer N Copray SC Boddeke HW Neuronal SLC (CCL21) expression: implications for the neuron-microglial signaling systemErnst Schering Res Found Workshop2002 394560

    Not in our library10.1007/978-3-662-05073-6_4

  47. 47.

    de Jong EK Dijkstra IM Hensens M Brouwer N van Amerongen M Liem RS Boddeke HW Biber K Vesicle-mediated transport and release of CCL21 in endangered neurons: a possible explanation for microglia activation remote from a primary lesionJ Neurosci2005 25754857

    Not in our library10.1523/jneurosci.1019-05.2005

  48. 48.

    Rothwell NJ Annual review prize lecture cytokines - killers in the brain?J Physiol1999 514Pt 1317

    Not in our library10.1111/j.1469-7793.1999.003af.x

  49. 49.

    Hans VH Imhof HG Stocker R Grob P Trentz O Morganti-Kossmann C Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuriesShock1995 43117

    Not in our library10.1097/00024382-199511000-00001

  50. 50.

    Camats J Hadberg H Quintana A Rojas S Giralt M Molinero A Campbell IL Hidalgo J Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglial degeneration induced by 6-aminonicotinamideJ Neurosci Res2003 7348196

    Not in our library10.1002/jnr.10681

  51. 51.

    Kremlev SG Palmer C Interleukin-10 inhibits endotoxin-induced pro-inflammatory cytokines in microglial cell culturesJ Neuroimmunol2005 1627180

    Not in our library10.1016/j.jneuroim.2005.01.010

  52. 52.

    Kim KS Wass CA Cross AS Opal SM Modulation of blood–brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the ratLymphokine Cytokine Res1992 112938

    Not in our library

  53. 53.

    Ramilo O Saez-Llorens X Mertsola J Jafari H Olsen KD Hansen EJ Yoshinaga M Ohkawara S Nariuchi H McCracken GH Jr Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammationJ Exp Med1990 172497507

    Not in our library10.1084/jem.172.2.497

  54. 54.

    Whalen MJ Clark RS Dixon CE Robichaud P Marion DW Vagni V Graham S Virag L Hasko G Stachlewitz R Szabo C Kochanek PM Traumatic brain injury in mice deficient in poly-ADP(ribose) polymerase: a preliminary reportActa Neurochir Suppl2000 76614

    Not in our library10.1007/978-3-7091-6346-7_12

  55. 55.

    Kordon C Bihoreau C Integrated communication between the nervous, endocrine and immune systemsHorm Res1989 311004

    Not in our library10.1159/000181096

  56. 56.

    Spangelo BL Gorospe WC Role of the cytokines in the neuroendocrine-immune system axisFront Neuroendocrinol1995 16122

    Not in our library10.1006/frne.1995.1001

  57. 57.

    Ban E Haour F Lenstra R Brain interleukin 1 gene expression induced by peripheral lipopolysaccharide administrationCytokine1992 44854

    Not in our library10.1016/1043-4666(92)90036-q

  58. 58.

    Ban E Marquette C Sarrieu A Fitzpatrick F Fillion G Milon G Rostene W Haour F Regulation of interleukin-1 receptor expression in mouse brain and pituitary by lipopolysaccharide and glucocorticoidsNeuroendocrinology1993 585817

    Not in our library10.1159/000126594

  59. 59.

    Breder CD Dinarello CA Saper CB Interleukin-1 immunoreactive innervation of the human hypothalamusScience1988 2403214

    Not in our library10.1126/science.3258444

  60. 60.

    Tran PB Miller RJ Chemokine receptors: signposts to brain development and diseaseNat Rev Neurosci2003 444455

    Not in our library10.1038/nrn1116

  61. 61.

    Bajetto A Bonavia R Barbero S Piccioli P Costa A Florio T Schettini G Glial and neuronal cells express functional chemokine receptor CXCR4 and its natural ligand stromal cell-derived factor 1J Neurochem1999 73234857

    Not in our library10.1046/j.1471-4159.1999.0732348.x

  62. 62.

    Rostene W Kitabgi P Parsadaniantz SM Chemokines: a new class of neuromodulator?Nat Rev Neurosci2007 8895903

    Not in our library10.1038/nrn2255

  63. 63.

    Zou YR Kottmann AH Kuroda M Taniuchi I Littman DR Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar developmentNature1998 3935959

    Not in our library10.1038/31269

  64. 64.

    Biber K Neumann H Inoue K Boddeke HW Neuronal 'On' and 'Off' signals control microgliaTrends Neurosci2007 30596602

    Not in our library10.1016/j.tins.2007.08.007

  65. 65.

    Harrison JKL Lukacs NW (eds): The chemokine receptors2007 Humana Press, New York

    Not in our library

  66. 66.

    Ransohoff RM Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiologyImmunity2009 3171121

    Not in our library10.1016/j.immuni.2009.09.010

  67. 67.

    Semple BD Kossmann T Morganti-Kossmann MC Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networksJ Cereb Blood Flow Metab2010 3045973

    Not in our library10.1038/jcbfm.2009.240

  68. 68.

    Wilson EH Weninger W Hunter CA Trafficking of immune cells in the central nervous systemJ Clin Invest2010 120136879

    Not in our library10.1172/jci41911

  69. 69.

    Conductier G Blondeau N Guyon A Nahon JL Rovère C The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseasesJ Neuroimmunol2010 22493100

    Not in our library10.1016/j.jneuroim.2010.05.010

  70. 70.

    Coughlan CM McManus CM Sharron M Gao Z Murphy D Jaffer S Choe W Chen W Hesselgesser J Gaylord H Kalyuzhny A Lee VM Wolf B Doms RW Kolson DL Expression of multiple functional chemokine receptors and monocyte chemoattractant protein-1 in human neuronsNeuroscience2000 97591600

    Not in our library10.1016/s0306-4522(00)00024-5

  71. 71.

    Yamamoto T Yamashita A Yamada K Hata R Immunohistochemical localization of chemokine CXCL14 in rat hypothalamic neuronsNeurosci Lett2011 48733540

    Not in our library10.1016/j.neulet.2010.10.051

  72. 72.
    Differential gene expression in LPS/IFNγ activated microglia and macrophages: in vitro versus in vivo · 2009
    No notice
  73. 73.

    de Haas AH van Weering HR de Jong EK Boddeke HW Biber KP Neuronal chemokines: versatile messengers in central nervous system cell interactionMol Neurobiol2007 3613751

    Not in our library10.1007/s12035-007-0036-8

  74. 74.

    Zhao P Waxman SG Hains BC Modulation of thalamic nociceptive processing after spinal cord injury through remote activation of thalamic microglia by cysteine cysteine chemokine ligand 21J Neurosci2007 278893902

    Not in our library10.1523/jneurosci.2209-07.2007

  75. 75.

    Biber K Sauter A Brouwer N Copray SC Boddeke HW Ischemia-induced neuronal expression of the microglia attracting chemokine Secondary Lymphoid-tissue Chemokine (SLC)Glia2001 3412133

    Not in our library10.1002/glia.1047

  76. 76.

    Rappert A Biber K Nolte C Lipp M Schubel A Lu B Gerard NP Gerard C Boddeke HW Kettenmann H Secondary lymphoid tissue chemokine (CCL21) activates CXCR3 to trigger a Cl- current and chemotaxis in murine microgliaJ Immunol2002 16832216

    Not in our library10.4049/jimmunol.168.7.3221

  77. 77.

    Rappert A Bechmann I Pivneva T Mahlo J Biber K Nolte C Kovac AD Gerard C Boddeke HW Nitsch R Kettenmann H CXCR3-dependent microglial recruitment is essential for dendrite loss after brain lesionJ Neurosci2004 2485009

    Not in our library10.1523/jneurosci.2451-04.2004

  78. 78.

    Ghirnikar RS Lee YL Eng LF Inflammation in traumatic brain injury: role of cytokines and chemokinesNeurochem Res1998 2332940

    Not in our library10.1023/a:1022453332560

  79. 79.

    Norris JG Tang LP Sparacio SM Benveniste EN Signal transduction pathways mediating astrocyte IL-6 induction by IL-1 beta and tumor necrosis factor-alphaJ Immunol1994 15284150

    Not in our library

  80. 80.

    Woodroofe MN Sarna GS Wadhwa M Hayes GM Loughlin AJ Tinker A Cuzner ML Detection of interleukin-1 and interleukin-6 in adult rat brain, following mechanical injury, by in vivo microdialysis: evidence of a role for microglia in cytokine productionJ Neuroimmunol1991 3322736

    Not in our library10.1016/0165-5728(91)90110-s

  81. 81.

    Taupin V Toulmond S Serrano A Benavides J Zavala F Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion. Influence of pre- and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligandJ Neuroimmunol1993 4217785

    Not in our library10.1016/0165-5728(93)90008-m

  82. 82.

    Walker PA Jimenez F Cox CS Jr Progenitor cell therapy for traumatic brain injury: effect of serum osmolarity on cell viability and cytokine productionRegen Med2010 56571

    Not in our library10.2217/rme.09.73

  83. 83.

    Morganti-Kossmann MC Satgunaseelan L Bye N Kossmann T Modulation of immune response by head injuryInjury2007 381392400

    Not in our library10.1016/j.injury.2007.10.005

  84. 84.

    Ajmo CT Jr Vernon DO Collier L Hall AA Garbuzova-Davis S Willing A Pennypacker KR The spleen contributes to stroke-induced neurodegenerationJ Neurosci Res2008 86222734

    Not in our library10.1002/jnr.21661

  85. 85.

    Rimaniol AC Lekieffre D Serrano A Masson A Benavides J Zavala F Biphasic transforming growth factor-beta production flanking the pro-inflammatory cytokine response in cerebral traumaNeuroreport1995 71336

    Not in our library

  86. 86.

    Adibhatla RM Hatcher JF Dempsey RJ Lipids and lipidomics in brain injury and diseasesAAPS J2006 8E31421

    Not in our library10.1007/bf02854902

  87. 87.
    Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor · 2012
    No notice
  88. 88.

    Bernardo A Minghetti L PPAR-gamma agonists as regulators of microglial activation and brain inflammationCurr Pharm Des2006 1293109

    Not in our library10.2174/138161206780574579

  89. 89.

    Konsman JP Drukarch B Van Dam AM (Peri)vascular production and action of pro-inflammatory cytokines in brain pathologyClin Sci (Lond)2007 112125

    Not in our library10.1042/cs20060043

  90. 90.

    Keel M Trentz O Pathophysiology of polytraumaInjury2005 36691709

    Not in our library10.1016/j.injury.2004.12.037

  91. 91.

    Smrcka M Mrlian A Karlsson-Valik J Klabusay M The effect of head injury upon the immune systemBratisl Lek Listy2007 1081448

    Not in our library

  92. 92.

    Wolach B Sazbon L Gavrieli R Broda A Schlesinger M Early immunological defects in comatose patients after acute brain injuryJ Neurosurg2001 9470611

    Not in our library10.3171/jns.2001.94.5.0706

  93. 93.

    Dziedzic T Slowik A Szczudlik A Nosocomial infections and immunity: lesson from brain-injured patientsCrit Care2004 826670

    Not in our library10.1186/cc2828

  94. 94.

    Becher B Prat A Antel JP Brain-immune connection: immuno-regulatory properties of CNS-resident cellsGlia2000 29293304

    Not in our library10.1002/(sici)1098-1136(20000215)29:4<293::aid-glia1>3.0.co;2-a

  95. 95.

    Mirzayan MJ Probst C Krettek C Samii M Pape HC van Griensven M Samii A Systemic effects of isolated brain injury: an experimental animal studyNeurol Res2008 3045760

    Not in our library10.1179/174313208x276907

  96. 96.

    Okuaki Y Miyazaki H Zeniya M Ishikawa T Ohkawa Y Tsuno S Sakaguchi M Hara M Takahashi H Toda G Splenectomy-reduced hepatic injury induced by ischemia/reperfusion in the ratLiver1996 1618894

    Not in our library10.1111/j.1600-0676.1996.tb00726.x

  97. 97.

    Li M Li F Luo C Shan Y Zhang L Qian Z Zhu G Lin J Feng H Immediate splenectomy decreases mortality and improves cognitive function of rats after severe traumatic brain injuryJ Trauma2011 711417

    Not in our library10.1097/ta.0b013e3181f30fc9

  98. 98.

    Lee ST Chu K Jung KH Kim SJ Kim DH Kang KM Hong NH Kim JH Ban JJ Park HK Kim SU Park CG Lee SK Kim M Roh JK Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic strokeBrain2008 13161629

    Not in our library10.1093/brain/awm306

  99. 99.

    Ajmo CT Jr Collier LA Leonardo CC Hall AA Green SM Womble TA Cuevas J Willing AE Pennypacker KR Blockade of adrenoreceptors inhibits the splenic response to strokeExp Neurol2009 2184755

    Not in our library10.1016/j.expneurol.2009.03.044

  100. 100.

    Stewart IB McKenzie DC The human spleen during physiological stressSports Med2002 323619

    Not in our library10.2165/00007256-200232060-00002

  101. 101.

    Guan J Jin D Jin L Apoptosis in multiple organs of rats in early stage of polytrauma combined with shockZhonghua Yi Xue Za Zhi1998 787415

    Not in our library

  102. 102.

    Campbell SJ Zahid I Losey P Law S Jiang Y Bilgen M van Rooijen N Morsali D Davis AE Anthony DC Liver Kupffer cells control the magnitude of the inflammatory response in the injured brain and spinal cordNeuropharmacology2008 557807

    Not in our library10.1016/j.neuropharm.2008.06.074

  103. 103.

    Campbell SJ Rob MJ D Yanyan J Carina F Pitossi FJ Anthony DC Overexpression of IL-1beta by adenoviral-mediated gene transfer in the rat brain causes a prolonged hepatic chemokine response, axonal injury and the suppression of spontaneous behaviourNeurobiol Dis2007 2715163

    Not in our library10.1016/j.nbd.2007.04.013

  104. 104.

    Campbell SJ Hughes PM Iredale JP Wilcockson DC Waters S Docagne F Perry VH Anthony DC CINC-1 is an acute-phase protein induced by focal brain injury causing leukocyte mobilization and liver injuryFASEB J2003 17116870

    Not in our library10.1096/fj.02-0757fje

  105. 105.

    Campbell SJ Perry VH Pitossi FJ Butchart AG Chertoff M Waters S Dempster R Anthony DC Central nervous system injury triggers hepatic CC and CXC chemokine expression that is associated with leukocyte mobilization and recruitment to both the central nervous system and the liverAm J Pathol2005 166148797

    Not in our library10.1016/s0002-9440(10)62365-6

  106. 106.

    Moinard C Severine G Valerie B Beatrice M Catherine M-L Jean-Claude C Luc C Christine C Evidence for impairment of hepatic energy homeostasis in head-injured ratJ Neurotrauma2008 251249

    Not in our library10.1089/neu.2007.0391

  107. 107.

    Kamm K Vanderkolk W Lawrence C Jonker M Davis AT The effect of traumatic brain injury upon the concentration and expression of interleukin-1beta and interleukin-10 in the ratJ Trauma2006 601527

    Not in our library10.1097/01.ta.0000196345.81169.a1

  108. 108.

    Namas R Ghuma A Hermus L Zamora R Okonkwo D Billiar TR Vodovotz Y The acute inflammatory response in trauma / hemorrhage and traumatic brain injury: current state and emerging prospectsLibyan J Med2009 497103

    Not in our library10.4176/090325

  109. 109.

    Smith RM Giannoudis PV Trauma and the immune responseJ R Soc Med1998 9141720

    Not in our library10.1177/014107689809100805

  110. 110.

    DiPiro JT Howdieshell TR Goddard JK Callaway DB Hamilton RG Mansberger AR Jr Association of interleukin-4 plasma levels with traumatic injury and clinical courseArch Surg1995 130115962Discussion, 1162–3

    Not in our library10.1001/archsurg.1995.01430110017004

  111. 111.

    Marcu AC Paccione KE Barbee RW Diegelmann RF Ivatury RR Ward KR Loria RM Androstenetriol immunomodulation improves survival in a severe trauma hemorrhage shock modelJ Trauma2007 636629

    Not in our library10.1097/ta.0b013e31802e70d9

  112. 112.

    Zamora R Vodovotz Y Billiar TR Inducible nitric oxide synthase and inflammatory diseasesMol Med2000 634773

    Not in our library

  113. 113.

    Hierholzer C Harbrecht B Menezes JM Kane J MacMicking J Nathan CF Peitzman AB Billiar TR Tweardy DJ Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shockJ Exp Med1998 18791728

    Not in our library10.1084/jem.187.6.917

  114. 114.

    Schutyser E Struyf S Van Damme J The CC chemokine CCL20 and its receptor CCR6Cytokine Growth Factor Rev2003 1440926

    Not in our library10.1016/s1359-6101(03)00049-2

  115. 115.

    Dieu-Nosjean MC Massacrier C Homey B Vanbervliet B Pin JJ Vicari A Lebecque S Dezutter-Dambuyant C Schmitt D Zlotnik A Caux C Macrophage inflammatory protein 3-alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursorsJ Exp Med2000 19270518

    Not in our library10.1084/jem.192.5.705

  116. 116.

    Chabaud M Page G Miossec P Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein 3-alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokinesJ Immunol2001 167601520

    Not in our library10.4049/jimmunol.167.10.6015

  117. 117.

    Matsui T Akahoshi T Namai R Hashimoto A Kurihara Y Rana M Nishimura A Endo H Kitasato H Kawai S Takagishi K Kondo H Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritisClin Exp Immunol2001 12515561

    Not in our library10.1046/j.1365-2249.2001.01542.x

  118. 118.

    Adams CW Bruton CJ The cerebral vasculature in dementia pugilisticaJ Neurol Neurosurg Psychiatry1989 526004

    Not in our library10.1136/jnnp.52.5.600

  119. 119.

    Masel BE DeWitt DS Traumatic brain injury: a disease process, not an eventJ Neurotrauma2010 27152940

    Not in our library10.1089/neu.2010.1358

  120. 120.

    Kiraly M Kiraly SJ Traumatic brain injury and delayed sequelae: a review–traumatic brain injury and mild traumatic brain injury (concussion) are precursors to later-onset brain disorders, including early-onset dementiaScientific World Journal2007 7176876

    Not in our library10.1100/tsw.2007.269

  121. 121.

    Emmerling MR Morganti-Kossmann MC Kossmann T Stahel PF Watson MD Evans LM Mehta PD Spiegel K Kuo YM Roher AE Raby CA Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta 42 in human CSF. A possible role for nerve cell injuryAnn N Y Acad Sci2000 90311822

    Not in our library10.1111/j.1749-6632.2000.tb06357.x

  122. 122.

    Van Den Heuvel C Thornton E Vink R Traumatic brain injury and Alzheimer's disease: a reviewProg Brain Res2007 16130316

    Not in our library10.1016/s0079-6123(06)61021-2

  123. 123.

    Johnson VE Stewart W Smith DH Widespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humansBrain Pathol221429

    Not in our library10.1111/j.1750-3639.2011.00513.x

  124. 124.

    Clinton J Ambler MW Roberts GW Post-traumatic Alzheimer's disease: preponderance of a single plaque typeNeuropathol Appl Neurobiol1991 176974

    Not in our library10.1111/j.1365-2990.1991.tb00695.x

  125. 125.

    Fleminger S Oliver D Lovestone S Rabe-Hesketh S Giora A Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replicationJ Neurol Neurosurg Psychiatry2003 7485762

    Not in our library10.1136/jnnp.74.7.857

  126. 126.

    Rudelli R Strom JO Welsh PT Ambler MW Posttraumatic premature Alzheimer's disease. Neuropathologic findings and pathogenetic considerationsArch Neurol1982 395705

    Not in our library10.1001/archneur.1982.00510210040009

  127. 127.

    Roberts GW Gentleman SM Lynch A Graham DI Beta A4 amyloid protein deposition in brain after head traumaLancet1991 33814223

    Not in our library10.1016/0140-6736(91)92724-g

  128. 128.

    Roberts GW Gentleman SM Lynch A Murray L Landon M Graham DI Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's diseaseJ Neurol Neurosurg Psychiatry1994 5741925

    Not in our library10.1136/jnnp.57.4.419

  129. 129.

    Gentleman SM Greenberg BD Savage MJ Noori M Newman SJ Roberts GW Griffin WS Graham DI A beta 42 is the predominant form of amyloid beta-protein in the brains of short-term survivors of head injuryNeuroreport1997 8151922

    Not in our library10.1097/00001756-199704140-00039

  130. 130.

    Ikonomovic MD Uryu K Abrahamson EE Ciallella JR Trojanowski JQ Lee VM Clark RS Marion DW Wisniewski SR DeKosky ST Alzheimer's pathology in human temporal cortex surgically excised after severe brain injuryExp Neurol2004 190192203

    Not in our library10.1016/j.expneurol.2004.06.011

  131. 131.

    Roberts GW Allsop D Bruton C The occult aftermath of boxingJ Neurol Neurosurg Psychiatry1990 533738

    Not in our library10.1136/jnnp.53.5.373

  132. 132.

    Horsburgh K Cole GM Yang F Savage MJ Greenberg BD Gentleman SM Graham DI Nicoll Beta-amyloid (Abeta)42(43), abeta42, abeta40 and apoE immunostaining of plaques in fatal head injuryNeuropathol Appl Neurobiol2000 2612432

    Not in our library10.1046/j.1365-2990.2000.026002124.x

  133. 133.

    Raby CA Morganti-Kossmann MC Kossmann T Stahel PF Watson MD Evans LM Mehta PD Spiegel K Kuo YM Roher AE Emmerling MR Traumatic brain injury increases beta-amyloid peptide 1–42 in cerebrospinal fluidJ Neurochem1998 7125059

    Not in our library10.1046/j.1471-4159.1998.71062505.x

  134. 134.

    McKenzie JE Gentleman SM Roberts GW Graham DI Royston MC Increased numbers of beta APP-immunoreactive neurones in the entorhinal cortex after head injuryNeuroreport1994 61614

    Not in our library10.1097/00001756-199412300-00041

  135. 135.

    Zhang B West EJ Van KC Gurkoff GG Zhou J Zhang XM Kozikowski AP Lyeth BG HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in ratsBrain Res2008 122618191

    Not in our library10.1016/j.brainres.2008.05.085

  136. 136.

    Marx F Blasko I Grubeck-Loebenstein B Mechanisms of immune regulation in Alzheimer's disease: a viewpointArch Immunol Ther Exp (Warsz)1999 472059

    Not in our library

  137. 137.

    Marx F Blasko I Zisterer K Grubeck-Loebenstein B Transfected human B cells: a new model to study the functional and immunostimulatory consequences of APP productionExp Gerontol1999 3478395

    Not in our library10.1016/s0531-5565(99)00049-2

  138. 138.

    Goldacre MJ Abisgold JD Yeates DGR Seagroatt V Risk of multiple sclerosis after head injury: record linkage studyJ Neurol Neurosurg Psychiatry2006 7735153

    Not in our library10.1136/jnnp.2005.077693

  139. 139.

    Kurland LT Trauma and multiple sclerosisAnn Neurol1994 36SupplS3337

    Not in our library10.1002/ana.410360711

  140. 140.

    Kang JH Lin HC Increased risk of multiple sclerosis after traumatic brain injury: a nationwide population-based studyJ Neurotrauma2012 299095

    Not in our library10.1089/neu.2011.1936

  141. 141.

    Sauerbeck A Hunter R Bing G Sullivan PG Traumatic brain injury and trichloroethylene exposure interact and produce functional, histological, and mitochondrial deficitsExp Neurol2012 2348594

    Not in our library10.1016/j.expneurol.2011.12.012

  142. 142.

    Hutson CB Lazo CR Mortazavi F Giza CC Hovda D Chesselet MF Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquatJ Neurotrauma2011 281783801

    Not in our library10.1089/neu.2010.1723

  143. 143.

    Faden AI Stoica B Neuroprotection: challenges and opportunitiesArch Neurol2007 64794800

    Not in our library10.1001/archneur.64.6.794

  144. 144.

    Stoica B Byrnes K Faden AI Multifunctional drug treatment in neurotraumaNeurotherapeutics2009 61427

    Not in our library10.1016/j.nurt.2008.10.029

  145. 145.

    Vink R Nimmo AJ Cernak I An overview of new and novel pharmacotherapies for use in traumatic brain injuryClin Exp Pharmacol Physiol2001 2891921

    Not in our library10.1046/j.1440-1681.2001.03548.x

  146. 146.

    Ziebell JM Morganti-Kossmann MC Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injuryNeurotherapeutics2010 72230

    Not in our library10.1016/j.nurt.2009.10.016

  147. 147.

    Dearden NM Gibson JS McDowell DG Effect of high-dose dexamethasone on outcome from severe head injuryJ Neurosurg1986 64818

    Not in our library10.3171/jns.1986.64.1.0081

  148. 148.

    Cederberg D Siesjo P What has inflammation to do with traumatic brain injury?Childs Nerv Syst2010 262216

    Not in our library10.1007/s00381-009-1029-x

  149. 149.

    Colak T Cine N Bamac B Kurtas O Ozbek A Bicer U Sunnetci D Savlı H Microarray-based gene expression analysis of an animal model for closed head injuryInjury2012 43126470

    Not in our library10.1016/j.injury.2012.01.021

  150. 150.

    Redell JB Liu Y Dash PK Traumatic brain injury alters expression of hippocampal microRNAs: potential regulators of multiple pathophysiological processesJ Neurosci Res2009 87143548

    Not in our library10.1002/jnr.21945

  151. 151.

    Degeorge ML Marlowe D Werner E Soderstrom KE Stock M Mueller A Bohn MC Kozlowski DA Combining glial cell line-derived neurotrophic factor gene delivery (AdGDNF) with L-arginine decreases contusion size but not behavioral deficits after traumatic brain injuryBrain Res2011 14034556

    Not in our library10.1016/j.brainres.2011.05.058

  152. 152.

    Markesbery WR Lovell MA Damage to lipids, proteins, DNA, and RNA in mild cognitive impairmentArch Neurol2007 649546

    Not in our library10.1001/archneur.64.7.954

  153. 153.

    Nelson PT Keller JN RNA in brain disease: no longer just "the messenger in the middle"J Neuropathol Exp Neurol2007 664618

    Not in our library10.1097/01.jnen.0000240474.27791.f3

  154. 154.

    Nelson PT Wang WX Rajeev BW MicroRNAs (miRNAs) in neurodegenerative diseasesBrain Pathol2008 181308

    Not in our library10.1111/j.1750-3639.2007.00120.x

  155. 155.

    Berezikov E Thuemmler F van Laake LW Kondova I Bontrop R Cuppen E Plasterk RH Diversity of microRNAs in human and chimpanzee brainNat Genet2006 3813757

    Not in our library10.1038/ng1914

  156. 156.

    Lei P Li Y Chen X Yang S Zhang J Microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injuryBrain Res2009 1284191201

    Not in our library10.1016/j.brainres.2009.05.074

  157. 157.

    Liu NK Wang XF Lu QB Xu XM Altered microRNA expression following traumatic spinal cord injuryExp Neurol2009 2194249

    Not in our library10.1016/j.expneurol.2009.06.015

  158. 158.

    Royo NC Shimizu S Schouten JW Stover JF McIntosh TK Pharmacology of traumatic brain injuryCurr Opin Pharmacol2003 32732

    Not in our library10.1016/s1471-4892(02)00006-1

  159. 159.

    Sinson G Voddi M McIntosh TK Combined fetal neural transplantation and nerve growth factor infusion: effects on neurological outcome following fluid-percussion brain injury in the ratJ Neurosurg1996 8465562

    Not in our library10.3171/jns.1996.84.4.0655

  160. 160.

    Philips MF Muir JK Saatman KE Raghupathi R Lee VM Trojanowski JQ McIntosh TK Survival and integration of transplanted postmitotic human neurons following experimental brain injury in immunocompetent ratsJ Neurosurg1999 9011624

    Not in our library10.3171/jns.1999.90.1.0116

  161. 161.

    Zhang C Saatman K Royo NC Soltesz KM Millard M Schouten JW Motta M Hoover RC McMillan A Watson DJ Lee VM Trojanowski JQ McIntosh TK Delayed transplantation of human neurons following brain injury in rats: a long-term graft survival and behavior studyJ Neurotrauma2005 22145674

    Not in our library10.1089/neu.2005.22.1456

  162. 162.

    Longhi L Watson DJ Saatman KE Thompson HJ Zhang C Fujimoto S Royo N Castelbuono D Raghupathi R Trojanowski JQ Lee VM Wolfe JH Stocchetti N McIntosh TK Ex vivo gene therapy using targeted engraftment of NGF-expressing human NT2N neurons attenuates cognitive deficits following traumatic brain injury in miceJ Neurotrauma2004 21172336

    Not in our library10.1089/neu.2004.21.1723

  163. 163.

    Longhi L Zanier ER Royo N Stocchetti N McIntosh TK Stem cell transplantation as a therapeutic strategy for traumatic brain injuryTranspl Immunol2005 151438

    Not in our library10.1016/j.trim.2005.09.003

  164. 164.

    Tate MC Fibronectin promotes survival and migration of primary neural stem cells transplanted into the traumatically injured mouse brainCell Transplant2002 11328395

    Not in our library

  165. 165.

    Englund U Bjorklund A Wictorin K Migration patterns and phenotypic differentiation of long-term expanded human neural progenitor cells after transplantation into the adult rat brainBrain Res Dev Brain Res2002 13412341

    Not in our library10.1016/s0165-3806(01)00330-3

  166. 166.

    Vescovi AL Gritti A Galli R Parati EA Isolation and intracerebral grafting of nontransformed multipotential embryonic human CNS stem cellsJ Neurotrauma1999 1668993

    Not in our library10.1089/neu.1999.16.689

  167. 167.

    Wennersten A Meier X Holmin S Wahlberg L Mathiesen T Proliferation, migration, and differentiation of human neural stem/progenitor cells after transplantation into a rat model of traumatic brain injuryJ Neurosurg2004 1008896

    Not in our library10.3171/jns.2004.100.1.0088

  168. 168.

    Hagan M Wennersten A Meijer X Holmin S Wahlberg L Mathiesen T Neuroprotection by human neural progenitor cells after experimental contusion in ratsNeurosci Lett2003 35114952

    Not in our library10.1016/j.neulet.2003.07.021

  169. 169.

    Mahmood A Lu D Chopp M Marrow stromal cell transplantation after traumatic brain injury promotes cellular proliferation within the brainNeurosurgery2004 55118593

    Not in our library10.1227/01.neu.0000141042.14476.3c

  170. 170.

    Mahmood A Lu D Yi L Chen JL Chopp M Intracranial bone marrow transplantation after traumatic brain injury improving functional outcome in adult ratsJ Neurosurg2001 9458995

    Not in our library10.3171/jns.2001.94.4.0589

  171. 171.

    Walker PA Harting MT Shah SK Day MC El Khoury R Savitz SI Baumgartner J Cox CS Jr Progenitor cell therapy for the treatment of central nervous system injury: a review of the state of current clinical trialsStem Cells Int2010 2010369578

    Not in our library10.4061/2010/369578

  172. 172.

    Bakhtiary M Marzban M Mehdizadeh M Joghataei MT Khoei S Pirhajati Mahabadi V Laribi B Tondar M Moshkforoush A Comparison of transplantation of bone marrow stromal cells (BMSC) and stem cell mobilization by granulocyte colony stimulating factor after traumatic brain injury in ratIran Biomed J2010 141429

    Not in our library

  173. 173.

    Skardelly M Gaber K Burdack S Scheidt F Hilbig H Boltze J Förschler A Schwarz S Schwarz J Meixensberger J Schuhmann MU Long-term benefit of human fetal neuronal progenitor cell transplantation in a clinically adapted model after traumatic brain injuryJ Neurotrauma2011 2840114

    Not in our library10.1089/neu.2010.1526

  174. 174.

    Lundberg C Field PM Ajayi YO Raisman G Bjorklund A Conditionally immortalized neural progenitor cell lines integrate and differentiate after grafting to the adult rat striatum. A combined autoradiographic and electron microscopic studyBrain Res1996 737295300

    Not in our library10.1016/0006-8993(96)00923-7

  175. 175.

    Renfranz PJ Cunningham MG McKay RD Region-specific differentiation of the hippocampal stem cell line HiB5 upon implantation into the developing mammalian brainCell1991 6671329

    Not in our library10.1016/0092-8674(91)90116-g

  176. 176.

    Sinden JD Rashid-Doubell F Kershaw TL Nelson A Chadwick A Jat PS Noble MD Hodges H Gray JA Recovery of spatial learning by grafts of a conditionally immortalized hippocampal neuroepithelial cell line into the ischaemia-lesioned hippocampusNeuroscience1997 81599608

    Not in our library10.1016/s0306-4522(97)00330-8

  177. 177.

    Ryder EF Snyder EY Cepko CL Establishment and characterization of multipotent neural cell lines using retrovirus vector-mediated oncogene transferJ Neurobiol1990 2135675

    Not in our library10.1002/neu.480210209

  178. 178.

    Huang H Chen L Sanberg P Cell therapy from bench to bedside translation in CNS neurorestoratology eraCell Med2010 11546

    Not in our library10.3727/215517910x516673

  179. 179.

    Xue S Zhang HT Zhang P Luo J Chen ZZ Jang XD Xu RX Functional endothelial progenitor cells derived from adipose tissue show beneficial effect on cell therapy of traumatic brain injuryNeurosci Lett2010 47318691

    Not in our library10.1016/j.neulet.2010.02.035

  180. 180.

    Geffner LF Santacruz P Izurieta M Flor L Maldonado B Auad AH Montenegro X Gonzalez R Silva F Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studiesCell Transplant2008 17127793

    Not in our library10.3727/096368908787648074

  181. 181.

    Zhang ZX Guan LX Zhang K Zhang Q Dai LJ A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injuryCytotherapy2008 101349

    Not in our library10.1080/14653240701883061

Cited by papers we hold 5

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.